Seong Lee, MD
Ophthalmology · Abilene, TXNPI 1669466769
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,994 of the $4,067 with a category attached, or 73.6%. 15 manufacturers reported payments, led by Roche TCRC, Inc. at 35.0% of the total.
Across 100 payments — averaging $40.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche TCRC, Inc.$1K
- Regeneron Healthcare Solutions, Inc.$562
- AbbVie$481
- Sandoz$318
- Bausch & Lomb, A Division Of Bausch Health US, LLC$265
- Genentech USA, Inc.$196
- plus $822 from 9 others
Across 508 payments — averaging $6417.39 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Genentech, Inc.$2.2M
- Regeneron$522K
- Hexal AG$249K
- Roche TCRC, Inc.$178K
- AbbVie$58K
- Janssen Research & Development, LLC$45K
- plus $44K from 2 others
What the payments were for
- Travel & lodging$1,07326%
- Food & beverage$2,99474%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche TCRC, Inc. | 3 | $1,423 |
| Regeneron Healthcare Solutions, Inc. | 19 | $562 |
| AbbVie(2 entities) | 24 | $481 |
| Sandoz | 12 | $318 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $265 |
| Genentech USA, Inc. | 6 | $196 |
| Coherus Oncology, Inc. | 8 | $196 |
| Astellas Pharma US Inc | 7 | $188 |
| Novartis | 1 | $122 |
| Harrow Eye, LLC | 4 | $81 |
| Alcon | 1 | $69 |
| ANI Pharmaceuticals, Inc. | 2 | $55 |
| Amgen | 2 | $43 |
| Eyepoint US, Inc. | 2 | $35 |
| Bausch & Lomb Americas Inc. | 2 | $33 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Non-Covered Product$1,423
- BUPARLISIB$122
How this compares
$4,067 in reported general payments places this provider in the 70th percentile of 1,355 ophthalmology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 17 | $10,770 |
| Prednisolone Acetate | 338 | $10,232 |
| Ketorolac Tromethamine | 158 | $4,283 |
| Ciprofloxacin Hcl | 273 | $3,183 |
| Latanoprost | 271 | $2,974 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 32 | $2,950 |
| ValacyclovirValacyclovir Hcl | 30 | $2,841 |
| Brimonidine Tartrate | 163 | $2,726 |
| Travoprost | 19 | $2,259 |
| Ofloxacin | 182 | $2,028 |
| Timolol Maleate | 126 | $941 |
| Acetazolamide | 18 | $925 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 46 | $751 |
| MoxifloxacinMoxifloxacin Hcl | 40 | $702 |
| Dorzolamide Hcl | 48 | $680 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis | $481 | $10,77017 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 1,355 ophthalmology providers in Texas.
Other ophthalmology in Abilene
- Michael SingerSan Antonio$1.8M
- Oluwatosin SmithDallas$1.5M
- Charles WykoffBellaire$1.5M
- John MichelettiHouston$916K
- Davinder GroverDallas$705K
- Christina WengHouston$676K
- Peter ChangHouston$656K
- Zaina Al-MohtasebHouston$636K
- Ashkan AbbeyDallas$559K
- Stephen SladeHouston$530K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.